AstraZeneca should not be overlooked for long
03/04/24 -"While AstraZeneca witnessed a phenomenal turnaround in the last decade, the share price has been quiet in the last two years as sentiment has been impacted by a range of factors including too-high ..."
Pages
61
Language
English
Published on
03/04/24
You may also be interested by these reports :
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...
25/11/25
Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...
21/11/25
Ever since Sandoz demerged from Novartis, the generics/biosimilars giant has been delivering on its promises, and remains well on track to achieve ...
19/11/25
AstraZeneca has been beating the street’s estimates over the last few quarters, on the back of strong growth momentum for its oncology, rare disease, ...